Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of Adjuvant Imatinib in Localised GIST
After 9.1 years of follow-up, a trend toward better long-term imatinib failure-free survival in imatinib treated patients was observed in high-risk subgroup